Eric Lim1, Andee Tay2, Jan Von Der Thusen3, Maxim B Freidin4, Vladimir Anikin2, Andrew G Nicholson3. 1. National Heart and Lung Division, Imperial College, London, United Kingdom; Academic Division of Thoracic Surgery, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: e.lim@rbht.nhs.uk. 2. Academic Division of Thoracic Surgery, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, United Kingdom. 3. National Heart and Lung Division, Imperial College, London, United Kingdom; Department of Histopathology, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, United Kingdom. 4. National Heart and Lung Division, Imperial College, London, United Kingdom; Academic Division of Thoracic Surgery, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, United Kingdom.
Abstract
OBJECTIVES: The ability to capture and characterize peripheral blood circulating tumor cells has the potential for the development of a blood test for cancer. The aim of this study was to evaluate the diagnostic performance of microfluidic technology as a proof-of-concept study. METHODS: Blood from patients undergoing surgery for known or suspected lung cancer was obtained and processed using a microfluidic biochip. Diagnostic performance was evaluated against the reference of cancer identified within surgically obtained formalin-fixed paraffin embedded specimens reported by a principal pathologist. Agreement was assessed in a sample reported by a second independent pathologist. Sensitivity- and specificity-weighted analyses were undertaken. RESULTS: From March 2011 to October 2012, 46 patients at our institution donated blood for research. Cancer was the underlying diagnosis in 43 (94%); 34 (79%) of the patients had primary lung cancer. The proportion of patients with cancer in which atypical cells suspicious for cancer were identified on hematoxylin and eosin staining was 16/43 (37%) by the principal pathologist and 10/17 (59%) by the second pathologist. On sensitivity-weighted analysis, the sensitivity of the biochip was 54% (95% confidence interval [CI], 37-72) and the specificity was 33% (95% CI, 2-91). On specificity-weighted analysis, the sensitivity was 43% (95% CI, 21-71) and the specificity was 100% (95% CI, 5-100). CONCLUSIONS: This work highlights the potential of microfluidic technology to develop a blood test for the diagnosis of cancer using peripheral blood; conventional clinical criteria can be used as a proof-of-concept of what may be possible with today's technology.
OBJECTIVES: The ability to capture and characterize peripheral blood circulating tumor cells has the potential for the development of a blood test for cancer. The aim of this study was to evaluate the diagnostic performance of microfluidic technology as a proof-of-concept study. METHODS: Blood from patients undergoing surgery for known or suspected lung cancer was obtained and processed using a microfluidic biochip. Diagnostic performance was evaluated against the reference of cancer identified within surgically obtained formalin-fixed paraffin embedded specimens reported by a principal pathologist. Agreement was assessed in a sample reported by a second independent pathologist. Sensitivity- and specificity-weighted analyses were undertaken. RESULTS: From March 2011 to October 2012, 46 patients at our institution donated blood for research. Cancer was the underlying diagnosis in 43 (94%); 34 (79%) of the patients had primary lung cancer. The proportion of patients with cancer in which atypical cells suspicious for cancer were identified on hematoxylin and eosin staining was 16/43 (37%) by the principal pathologist and 10/17 (59%) by the second pathologist. On sensitivity-weighted analysis, the sensitivity of the biochip was 54% (95% confidence interval [CI], 37-72) and the specificity was 33% (95% CI, 2-91). On specificity-weighted analysis, the sensitivity was 43% (95% CI, 21-71) and the specificity was 100% (95% CI, 5-100). CONCLUSIONS: This work highlights the potential of microfluidic technology to develop a blood test for the diagnosis of cancer using peripheral blood; conventional clinical criteria can be used as a proof-of-concept of what may be possible with today's technology.
Authors: Dimple Y Chudasama; Daria V Freydina; Maxim B Freidin; Maria Leung; Angeles Montero Fernandez; Alexandra Rice; Andrew G Nicholson; Emmanouil Karteris; Vladimir Anikin; Eric Lim Journal: Ann Transl Med Date: 2016-12
Authors: Jay F Dorsey; Gary D Kao; Kelly M MacArthur; Melody Ju; David Steinmetz; E Paul Wileyto; Charles B Simone; Stephen M Hahn Journal: Cancer Date: 2014-09-19 Impact factor: 6.860